Childhood predictors of adult fatty liver. The Cardiovascular Risk in Young Finns Study

Journal of Hepatology

Volumn 65, Issue 4, 2016, Pages 784-790

  Suomela, Emmi ^a   Oikonen, Mervi ^a   Pitkänen, Niina ^a   Ahola Olli, Ari ^a   Virtanen, Johanna ^b   Parkkola, Riitta ^b   Jokinen, Eero ^c   Laitinen, Tomi ^d   Hutri Kähönen, Nina ^e   Kähönen, Mika ^e   Lehtimäki, Terho ^e   Taittonen, Leena ^f   Tossavainen, Päivi ^g   Jula, Antti ^h   Loo, Britt Marie ^h   Mikkilä, Vera ^a,c   Telama, Risto ⁱ   Viikari, Jorma S A ^b   Juonala, Markus ^b   Raitakari, Olli T ^a,b  

^a UNIVERSITY OF TURKU   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d UNIVERSITY OF EASTERN FINLAND   (Finland)

^e TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^f UNIVERSITY OF OULU   (Finland)

^g OULU UNIVERSITY HOSPITAL   (Finland)

^h NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

ⁱ LIKES RESEARCH CENTER FOR SPORT AND HEALTH SCIENCES   (Finland)

Author keywords

Hepatic steatosis; Longitudinal study; Population study; Risk factors

Indexed keywords

C REACTIVE PROTEIN; INSULIN; MEMBRANE PROTEIN; TRIACYLGLYCEROL LIPASE;

ADULT; ADULT DISEASE; AGE; ALLELE; ARTICLE; BIRTH WEIGHT; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR RISK; CHILD; CHILDHOOD; COHORT ANALYSIS; ETHNIC GROUP; FATTY LIVER; FEMALE; FINNISH (PEOPLE); GENE; GENETIC RISK; HUMAN; INSULIN BLOOD LEVEL; LIFESTYLE; LIPID BLOOD LEVEL; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PHYSICAL ACTIVITY; PNPLA3 GENE; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SMALL FOR DATE INFANT; SMOKING; TM6SF2 GENE; ADOLESCENT; CARDIOVASCULAR DISEASE; FINLAND; GENETIC PREDISPOSITION; LIVER; RISK FACTOR;

ADOLESCENT; CARDIOVASCULAR DISEASES; CHILD; FATTY LIVER; FINLAND; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIPASE; LIVER; LONGITUDINAL STUDIES; MEMBRANE PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 84991696056     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.05.020     Document Type: Article

References (51)

1. [1] G. Targher, C.P. Day, Bonora, E., Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 363 (2010), 1341–1350.
2. [2] Alisi, A., Manco, M., Vania, A., Nobili, V., Pediatric nonalcoholic fatty liver disease in 2009. J Pediatr 155 (2009), 469–474.
3. [3] Patton, H.M., Sirlin, C., Behling, C., Middleton, M., Schwimmer, J.B., Lavine, J.E., Pediatric nonalcoholic fatty liver disease: a critical appraisal of current data and implications for future research. J Pediatr Gastroenterol Nutr 43 (2006), 413–427.
4. [4] Angulo, P., Nonalcoholic fatty liver disease. N Engl J Med 346 (2002), 1221–1231.
5. [5] Reue, K., A thematic review series: lipid droplet storage and metabolism: from yeast to man. J Lipid Res 52 (2011), 1865–1868.
6. [6] Quiroga, A.D., Lehner, R., Liver triacylglycerol lipases. Biochim Biophys Acta 2012 (1821), 762–769.
7. [7] Dongiovanni, P., Romeo, S., Valenti, L., Genetic factors in the pathogenesis of nonalcoholic fatty liver and steatohepatitis. Biomed Res Int, 2015, 2015, 460190.
8. [8] Byrne, C.D., Ectopic fat, insulin resistance and non-alcoholic fatty liver disease. Proc Nutr Soc 72 (2013), 412–419.
9. [9] Birkenfeld, A.L., Shulman, G.I., Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology 59 (2014), 713–723.
10. [10] S. Romeo, J. Kozlitina, Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L.A., et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 40 (2008), 1461–1465.
11. [11] Macaluso, F.S., Maida, M., Petta, S., Genetic background in nonalcoholic fatty liver disease: A comprehensive review. World J Gastroenterol 21 (2015), 11088–11111.
12. [12] Dongiovanni, P., Valenti, L., Genetics of nonalcoholic fatty liver disease. Metabolism, 2015.
13. [13] J. Kozlitina, E. Smagris, Stender, S., Nordestgaard, B.G., Zhou, H.H., Tybjaerg-Hansen, A., et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 46 (2014), 352–356.
14. [14] O.L. Holmen H. Zhang Y. Fan, Hovelson, D.H., Schmidt, E.M., Zhou, W., et al. Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk. Nat Genet 46 (2014), 345–351.
15. [15] Liu, Y.L., Reeves, H.L., Burt, A.D., Tiniakos, D., McPherson, S., Leathart, J.B., et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun, 5, 2014, 4309.
16. [16] P. Dongiovanni S. Petta, Maglio, C., Fracanzani, A.L., Pipitone, R., Mozzi, E., et al. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology 61 (2015), 506–514.
17. [17] Sookoian, S., Castano, G.O., Scian, R., Mallardi, P., Fernandez Gianotti, T., Burgueno, A.L., et al. Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity. Hepatology 61 (2015), 515–525.
18. [18] Petta, S., Miele, L., Bugianesi, E., Camma, C., Rosso, C., Boccia, S., et al. Glucokinase regulatory protein gene polymorphism affects liver fibrosis in non-alcoholic fatty liver disease. PLoS One, 9, 2014, e87523.
19. [19] Beer, N.L., Tribble, N.D., McCulloch, L.J., Roos, C., Johnson, P.R., Orho-Melander, M., et al. The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver. Hum Mol Genet 18 (2009), 4081–4088.
20. [20] Raitakari, O.T., Juonala, M., Rönnemaa, T., Keltikangas-Järvinen, L., Räsänen, L., Pietikäinen, M., et al. Cohort profile: the Cardiovascular Risk in Young Finns Study. Int J Epidemiol 37 (2008), 1220–1226.
21. [21] Edens, M.A., van Ooijen, P.M., Post, W.J., Haagmans, M.J., Kristanto, W., Sijens, P.E., et al. Ultrasonography to quantify hepatic fat content: validation by 1H magnetic resonance spectroscopy. Obesity (Silver Spring) 17 (2009), 2239–2244.
22. [22] Saverymuttu, S.H., Joseph, A.E., Maxwell, J.D., Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J (Clin Res Ed) 292 (1986), 13–15.
23. [23] Telama, R., Viikari, J., Välimäki, I., Siren-Tiusanen, H., Åkerblom, H.K., Uhari, M., et al. Atherosclerosis precursors in Finnish children and adolescents. X. Leisure-time physical activity. Acta Paediatr Scand Suppl 318 (1985), 169–180.
24. [24] Herbert, V., Lau, K.S., Gottlieb, C.W., Bleicher, S.J., Coated charcoal immunoassay of insulin. J Clin Endocrinol Metab 25 (1965), 1375–1384.
25. [25] Porkka, K.V., Raitakari, O.T., Leino, A., Laitinen, S., Räsänen, L., Rönnemaa, T., et al. Trends in serum lipid levels during 1980–1992 in children and young adults. The Cardiovascular Risk in Young Finns Study. Am J Epidemiol 146 (1997), 64–77.
26. [26] Juonala, M., Viikari, J.S., Hutri-Kähönen, N., Pietikäinen, M., Jokinen, E., Taittonen, L., et al. The 21-year follow-up of the Cardiovascular Risk in Young Finns Study: risk factor levels, secular trends and east-west difference. J Intern Med 255 (2004), 457–468.
27. [27] Juonala, M., Viikari, J.S., Rönnemaa, T., Taittonen, L., Marniemi, J., Raitakari, O.T., Childhood C-reactive protein in predicting CRP and carotid intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study. Arterioscler Thromb Vasc Biol 26 (2006), 1883–1888.
28. [28] E.K. Speliotes L.M. Yerges-Armstrong J. Wu R. Hernaez L.J. Kim, Palmer, C.D., et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet, 7, 2011, e1001324.
29. [29] Pencina, M.J., D'Agostino, R.B. Sr, D'Agostino, R.B. Jr, Vasan, R.S., Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27 (2008), 157–172 [Discussion 207–212].
30. [30] Suomela, E., Oikonen, M., Virtanen, J., Parkkola, R., Jokinen, E., Laitinen, T., et al. Prevalence and determinants of fatty liver in normal-weight and overweight young adults. The Cardiovascular Risk in Young Finns Study. Ann Med, 2014, 1–7.
31. [31] Cohen, J.C., Horton, J.D., Hobbs, H.H., Human fatty liver disease: old questions and new insights. Science 332 (2011), 1519–1523.
32. [32] Sandboge, S., Perälä, M.M., Salonen, M.K., Blomstedt, P.A., Osmond, C., Kajantie, E., et al. Early growth and non-alcoholic fatty liver disease in adulthood-the NAFLD liver fat score and equation applied on the Helsinki Birth Cohort Study. Ann Med 45 (2013), 430–437.
33. [33] Breij, L.M., Kerkhof, G.F., Hokken-Koelega, A.C., Accelerated infant weight gain and risk for nonalcoholic fatty liver disease in early adulthood. J Clin Endocrinol Metab 99 (2014), 1189–1195.
34. [34] Faienza, M.F., Brunetti, G., Ventura, A., D'Aniello, M., Pepe, T., Giordano, P., et al. Nonalcoholic fatty liver disease in prepubertal children born small for gestational age: influence of rapid weight catch-up growth. Horm Res Paediatr 79 (2013), 103–109.
35. [35] Dulloo, A.G., Regulation of fat storage via suppressed thermogenesis: a thrifty phenotype that predisposes individuals with catch-up growth to insulin resistance and obesity. Horm Res 65 (2006), 90–97.
36. [36] Ibanez, L., Ong, K., Dunger, D.B., de Zegher, F., Early development of adiposity and insulin resistance after catch-up weight gain in small-for-gestational-age children. J Clin Endocrinol Metab 91 (2006), 2153–2158.
37. [37] Barker, D.J., Fetal origins of coronary heart disease. BMJ 311 (1995), 171–174.
38. [38] Morrison, J.L., Duffield, J.A., Muhlhausler, B.S., Gentili, S., McMillen, I.C., Fetal growth restriction, catch-up growth and the early origins of insulin resistance and visceral obesity. Pediatr Nephrol 25 (2010), 669–677.
39. [39] Marzuillo, P., Del Giudice, E.M., Santoro, N., Pediatric non-alcoholic fatty liver disease: New insights and future directions. World J Hepatol 6 (2014), 217–225.
40. [40] P. Pingitore C. Pirazzi, Mancina, R.M., Motta, B.M., Indiveri, C., Pujia, A., et al. Recombinant PNPLA3 protein shows triglyceride hydrolase activity and its I148M mutation results in loss of function. Biochim Biophys Acta 1841 (2014), 574–580.
41. [41] Dongiovanni, P., Donati, B., Fares, R., Lombardi, R., Mancina, R.M., Romeo, S., et al. PNPLA3 I148M polymorphism and progressive liver disease. World J Gastroenterol 19 (2013), 6969–6978.
42. [42] Donati, B., Motta, B.M., Pingitore, P., Meroni, M., Pietrelli, A., Alisi, A., et al. The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage. Hepatology 63 (2016), 787–798.
43. [43] C. Pirazzi M. Adiels, Burza, M.A., Mancina, R.M., Levin, M., Stahlman, M., et al. Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro. J Hepatol 57 (2012), 1276–1282.
44. [44] Yki-Järvinen, H., Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol 2 (2014), 901–910.
45. [45] Yki-Järvinen, H., Luukkonen, P.K., Heterogeneity of non-alcoholic fatty liver disease. Liver Int 35 (2015), 2498–2500.
46. [46] Bhatia, L.S., Curzen, N.P., Calder, P.C., Byrne, C.D., Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?. Eur Heart J 33 (2012), 1190–1200.
47. [47] Al Knawy, B., Shiffman, M., Percutaneous liver biopsy in clinical practice. Liver Int 27 (2007), 1166–1173.
48. [48] Ratziu, V., Charlotte, F., Heurtier, A., Gombert, S., Giral, P., Bruckert, E., et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 128 (2005), 1898–1906.
49. [49] AlShaalan, R., Aljiffry, M., Al-Busafi, S., Metrakos, P., Hassanain, M., Nonalcoholic fatty liver disease: Noninvasive methods of diagnosing hepatic steatosis. Saudi J Gastroenterol 21 (2015), 64–70.
50. [50] Saadeh, S., Younossi, Z.M., Remer, E.M., Gramlich, T., Ong, J.P., Hurley, M., et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 123 (2002), 745–750.
51. [51] R. Hernaez M. Lazo, Bonekamp, S., Kamel, I., Brancati, F.L., Guallar, E., et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 54 (2011), 1082–1090.